MBX Biosciences, Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.98M | 9.86M | 8.86M | 8.13M | 6.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.19M | 59.58M | 50.91M | 42.26M | 35.31M |
| Operating Income | -68.19M | -59.58M | -50.91M | -42.26M | -35.31M |
| Income Before Tax | -61.92M | -55.18M | -47.20M | -38.95M | -32.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.92 | -55.18 | -47.20 | -38.95 | -32.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.92M | -55.18M | -47.20M | -38.95M | -32.56M |
| EBIT | -68.19M | -59.58M | -50.91M | -42.26M | -35.31M |
| EBITDA | -67.95M | -59.35M | -50.72M | -42.09M | -35.15M |
| EPS Basic | -26.13 | -33.39 | -40.00 | -35.06 | -31.75 |
| Normalized Basic EPS | -16.39 | -21.44 | -25.57 | -22.49 | -20.41 |
| EPS Diluted | -26.13 | -33.39 | -40.00 | -35.06 | -31.75 |
| Normalized Diluted EPS | -16.39 | -21.44 | -25.57 | -22.49 | -20.41 |
| Average Basic Shares Outstanding | 42.37M | 10.12M | 4.68M | 4.42M | 4.07M |
| Average Diluted Shares Outstanding | 42.37M | 10.12M | 4.68M | 4.42M | 4.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |